Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Leukemia 1Kidney Neoplasms 1High-risk Leukemias 1Glioblastoma 1Esophageal Neoplasms 1Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Bronchogenic 1

Interventions

selpercatinib 2pembrolizumab 2130-nm albumin-bound paclitaxel 2vandetanib 1trametinib 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1methyl N-acetylsibirosaminide 1lenvatinib 1fludarabine 1cemiplimab 1alectinib 1aldesleukin 1Thyrotropin Alfa 1Presenilin-1 1Panitumumab 1Interleukin-15 1Imatinib Mesylate 1IT-101 1IFL protocol 1Gemcitabine 1Dacarbazine 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Cetuximab 1Capecitabine 1Camptothecin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid Neoplasms × Interleukin-15 × Clear all
NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡